Side-by-side · Research reference

ACE-031vsEpitalon

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

APhase 2HUMAN-REVIEWED10/44 cited

BHuman-MechanisticAUTO-DRAFTED8/37 cited

ACE-031

ActRIIB-Fc Fusion · Phase 2 Halted

Phase 2Highest trial stage

2011Development halted

~58.4 kDaMolecular weightReichel 2025

SQ · Weekly dosing investigated

Epitalon

Pineal bioregulator · Telomerase activator

5–10 mgPer cycle doseKhavinson 2003

HumanMechanisticKhavinson 2003

HoursHalf-life (est)

SQ or IM · Abdomen · Daily for 10–20 days

01Mechanism of Action

Parameter

ACE-031

Epitalon

Primary target

Myostatin, GDF11, activin A — TGF-β superfamily ligands

Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003

Pathway

Soluble decoy receptor binds circulating myostatin/TGF-β ligands → prevents ActRIIB activation → SMAD2/3 pathway inhibition

Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003

Downstream effect

Disinhibition of myogenic signaling, increased skeletal muscle mass and strength

Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003

Feedback intact?

—

Origin

Recombinant fusion protein: human ActRIIB extracellular domain + IgG1-Fc fragmentReichel 2025

Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003

Antibody development

—

02Dosage Protocols

Parameter

ACE-031

Epitalon

Clinical dosing

Weekly or biweekly SQ injections (exact doses undisclosed pre-halt)

Phase 2 DMD trial protocol not fully published.

—

Black market products

Variable purity; 12/14 tested products contained target protein plus contaminantsReichel 2025

SDS-PAGE revealed multiple protein bands; quality control absent.Reichel 2025

—

Evidence basis

Phase 2 trial discontinued — incomplete dataset

In-vitro telomerase + Russian clinical trialsKhavinson 2003

Half-life

Days to weeks (Fc-fusion typical kinetics)

IgG1-Fc domain confers extended circulation time.

Hours (estimated)

Duration investigated

12–24 weeks (trial cut short)

—

Standard dose

—

5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003

Anecdotal community protocol. Russian clinical literature uses similar cycling.

Frequency

—

Once daily during a cycle

Lower / starter dose

—

2.5 mg / day

Duration

—

10–20 day cycles, 1–2× per year

Reconstitution

—

Bacteriostatic water

Timing

—

Pre-sleep preferred (pineal alignment)

04Side Effects & Safety

Parameter

ACE-031

Epitalon

Epistaxis (nosebleeds)

Significant incidence in Phase 2 DMD trial — primary safety signal

—

Telangiectasia

Dilated capillaries / spider veins observed

—

Vascular abnormalities

Mechanism: ActRIIB/ALK1 pathway disruption affects vascular homeostasis

—

Injection site reactions

Local erythema, induration (biologics class effect)

—

Antibody development

Potential for anti-drug antibodies (Fc-fusion proteins); incidence not reported

—

Black market contaminants

12/14 tested products contained multiple unidentified proteins alongside ACE-031Reichel 2025

—

Injection site reaction

—

Mild irritation

Sleep architecture

—

Improved subjective sleep quality (anecdotal)

Cancer risk

—

Theoretical via telomerase activation in pre-malignant cells

Long-term safety

—

Limited Western RCT data

Pregnancy / OB

—

Avoid

Antibody formation

—

Not reported

Absolute Contraindications

ACE-031

·History of vascular disorders (epistaxis, telangiectasia, HHT)
·Pregnancy (TGF-β pathway critical for fetal development)
·Active malignancy (myostatin inhibition may affect tumour growth)
·Use of non-pharmaceutical grade ACE-031 (contamination risk)Reichel 2025

Epitalon

·Pregnancy / breastfeeding
·Active malignancy or pre-malignant state

Relative Contraindications

ACE-031

·Coagulation disorders or anticoagulant use (epistaxis risk)
·Hereditary hemorrhagic telangiectasia (HHT) family history
·Cardiovascular disease (vascular remodeling effects unknown)

Epitalon

·Family history of cancer

05Administration Protocol

Parameter

ACE-031

Epitalon

1. Pharmaceutical status

ACE-031 is not FDA-approved or commercially available. Phase 2 development was discontinued in 2011 due to safety concerns. Any ACE-031 on the black market is unregulated research chemical.

Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.

2. Black market quality

12 of 14 tested black market ACE-031 products contained the target protein but also carried multiple unidentified protein contaminants detectable by SDS-PAGE. Two products contained no ACVR2B-immunoreactive material.Reichel 2025

SQ — abdomen preferred. Rotate sites.

3. Detection in sport

ACE-031 is prohibited under WADA S4.3 (Myostatin Inhibitors). Gel electrophoresis and Western blotting using ACVR2B-specific antibodies can detect the ~58.4 kDa protein in biological samples.Reichel 2025

Pre-sleep preferred to align with pineal axis.

4. Clinical trial route

Phase 2 protocol used subcutaneous injections at weekly or biweekly intervals. Exact dosing protocols remain unpublished.

Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

—

29–31G, 4–8 mm insulin syringe.